The organization widely regarded as the leading authority on transgender medical treatment is facing allegations from the that it built influential treatment guidelines for minors on evidence its own leaders privately acknowledged was limited and uncertain.
The complaint, filed in a Texas federal court by the Federal Trade Commission and the attorneys general of Alaska, Iowa, Nebraska and Texas, accuses World Professional Association for Transgender Health (WPATH) of developing and promoting guidance that relied upon when recommending puberty blockers, cross-sex hormones and sex-change procedures for minors.
The case could determine whether the medical guidance that shaped transgender treatment for thousands of children was built on solid evidence or agenda-driven speculation.
FTC Chairman Andrew Ferguson said the lawsuit is a consumer-protection case focused on whether families were properly informed about the risks and benefits of these treatments.
“Children, but especially their parents, must have complete and truthful information when making decisions to purchase medical services,” Ferguson said in a statement. “For decades, the entities that make deceptive and unsubstantiated health-related claims.”
At the center of the lawsuit are allegations that WPATH publicly described its Standards of Care as evidence-based and rooted in expert consensus while some of the organization’s own leaders privately acknowledged limitations in the available evidence.
The complaint cites a 2023 strategy memo from Standards of Care 8th edition lead author Dr. Eli Coleman stating that “all of us are painfully aware that there are to back up our recommendations.”
It also references comments from Dr. Amy Tishelman, lead author of the organization’s chapter on children, who acknowledged in an NPR interview that there was no established “research basis” for determining the best assessments or treatments for “transgender youth.”
Federal regulators further allege WPATH removed age minimums from its 2022 Standards of Care for procedures including breast removal surgeries without scientific justification. According to the complaint, internal discussions revealed some WPATH leaders struggled to identify .
Kurt Miceli, chief medical officer for Do No Harm, a medical ethics advocacy organization, said the allegations raise serious questions about how the organization’s guidelines were developed.
“The of interest that are within the standards of care are significant, and again, not brought to light, and this is part of that deception, and the concern that WPATH has sort of stated that the science is there behind pediatric medical transition when it is not.”
Federal regulators allege that many of the clinicians and surgeons who helped draft WPATH’s guidelines had financial and professional interests tied to the treatments being recommended.
“What WPATH did was stack the deck with folks who had a financial invested interest in promoting pediatric medical transition, and subsequently you get guidelines that push hormones, puberty blockers, and surgeries,” Miceli said.
The lawsuit argues WPATH’s influence extends far beyond its membership. Its Standards of Care have been widely cited throughout medicine and have helped shape treatment protocols, and professional guidance across the United States.
WPATH is a co-sponsoring organization of ‘s widely used clinical practice guideline on gender dysphoria and gender incongruence. The American Academy of Child and Adolescent Psychiatry describes WPATH and Endocrine Society guidance as the two most widely known clinical guidelines used by providers caring for youth with gender dysphoria.
Among the most serious allegations are claims that WPATH promoted pediatric transition procedures as “lifesaving” despite insufficient evidence that such interventions reduce suicide risk.
The complaint cites instances in
